A new study reports the 5-year patient-reported outcome data from a population-based cohort of men with localized prostate cancer. These findings in conjunction with data on survival, treatment burden and treatment cost can assist clinicians in explaining to newly diagnosed patients the likely effects of modern management options on quality of life.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Howlader, N. et al. SEER cancer statistics review (CSR)1975–2016. National Cancer Institute https://seer.cancer.gov/csr/1975_2016/ (2019).
Weiner, A. B. et al. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis. 19, 395–397 (2016).
Hoffman, K. E. et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 323, 149–163 (2020).
McHorney, C. A., Ware, J. E. Jr & Raczek, A. E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 31, 247–263 (1993).
Szymanski, K. M. et al. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 76, 1245–1250 (2010).
Ousmen, A. et al. Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review. Health Qual. Life Outcomes 16, 228 (2018).
Skolarus, T. A. et al. Minimally important difference for the expanded prostate cancer index composite short form. Urology 85, 101–105 (2015).
Jayadevappa, R. et al. Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors. Health Serv. Res. 47, 1902–1925 (2012).
Sav, A. et al. Burden of treatment for chronic illness: a concept analysis and review of the literature. Health Expect. 18, 312–324 (2015).
Sharma, V. et al. Cost-effectiveness of active surveillance, radical prostatectomy and external beam radiotherapy for localized prostate cancer: an analysis of the ProtecT trial. J. Urol. 202, 964–972 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.R.S. has received support to his institution for research from Astellas Pharma, Celgene, Bayer, Bionomics, Medivation, Sanofi, Pfizer, AstraZeneca, Bristol-Myers Squibb, Roche, Amgen, Merck Sharp & Dohme and Tilray. He has also received travel, accommodations and expenses from Medivation/Pfizer. R.M.-B. declares no competing interests.
Rights and permissions
About this article
Cite this article
Mercieca-Bebber, R., Stockler, M.R. Patient-reported outcomes and localized prostate cancer management. Nat Rev Urol 17, 257–258 (2020). https://doi.org/10.1038/s41585-020-0303-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-020-0303-2